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Abstract
DNA microarrays have been widely applied to cancer
transcriptome analysis; however, the majority of such
data are not easily accessible or comparable. Further-
more, several important analytic approaches have
been applied to microarray analysis; however, their
application is often limited. To overcome these limita-
tions, we have developed Oncomine, a bioinformatics
initiative aimed at collecting, standardizing, analyzing,
and delivering cancer transcriptome data to the bio-
medical research community. Our analysis has identi-
fied the genes, pathways, and networks deregulated
across 18,000 cancer gene expression microarrays,
spanning the majority of cancer types and subtypes.
Here, we provide an update on the initiative, describe the
database and analysis modules, and highlight several
notable observations. Results from this comprehensive
analysis are available at http://www.oncomine.org.
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Introduction
In the last 5 years, hundreds of large-scale DNA microarray
experiments have been performed, generating global quan-
titative profiles of gene expression in cancer. Known types
and subtypes of cancer have been readily distinguished
by their gene expression patterns; more importantly, novel
molecular subtypes of cancer that are associated with a
myriad of tumor properties, including mechanism of trans-
formation, propensity to metastasize, and sensitivity or re-
sistance to particular therapies, have been discovered
(reviewed by Chung et al. [1]). Furthermore, numerous
candidate biomarkers and therapeutic targets have been
identified. Although such microarray studies have made
great strides in elucidating the molecular underpinnings
of cancer, in most cases, the invaluable data generated
from these studies sit stagnant and underused after publi-
cation. Microarray repositories, such as GEO and Array-
Express [2,3], and journal requirements to deposit microarray
data before publication have begun to ameliorate this prob-
lem; however, it remains difficult to ask targeted biologic ques-
tions of the collective transcriptome data set. For example, one
might wish to know in which molecular subtypes of leukemia a
tyrosine kinase of interest is most highly expressed, or, across
all relevant data sets, in which solid tumors relative to their re-
spective normal tissues the kinase most overexpressed. Other
high-level analytic queries might explore which transcription
factor binding sites are most prevalent in promoters of genes
overexpressed in a particular cancer, or which pathways or
interaction networks have disproportionate overexpression or
underexpression. One might also ask, ‘‘Of all cancer types
and subtypes, which has the profile most similar to that of a
cancer type of interest?’’—perhaps finding that BRAF mutant
thyroid cancer shares a strong similarity with Ras mutant
leukemia, reflecting their common transforming pathway. The
Oncomine initiative seeks to collect all published cancer micro-
array data and to perform standard analyses that allow re-
searchers to easily address such questions. To date, the effort
has amassed 18,000 cancer gene expression experiments,
and automated analysis has identified the genes, pathways,
regulatory networks, and functional networks activated and
repressed in human cancer.
Oncomine Overview
The first version of Oncomine was released in October 2003,
with 40 microarray data sets and nearly 100 differential expres-
sion analyses, allowing users to query differential expression
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results for a gene of interest across collected data sets [4]. A
meta-analysis of the 40 data sets identified a ‘‘universal’’
cancer signature, representing genes significantly over-
expressed in nearly all cancer types relative to normal tissue
types from which they arose [5]. Similarly, meta-analysis
extracted an undifferentiated cancer signature, representing
genes commonly activated in poorly differentiated cancers
relative to their well-differentiated counterparts, suggesting
common transcriptional mechanisms of dedifferentiation.
Oncomine 2.0 was released in October 2004, increasing
the number of analyzed data sets to 65 and adding a co-
expression module. In addition, an improved user interface
was developed, and scalable vector graphics (SVG) were
adopted for visualizing gene expression data and analysis.
Later, Enrichment Analysis was added to Oncomine 2.0, in-
cluding an analysis of transcription factor binding sites and
their distribution among Oncomine cancer signatures, which
led to the identification of several hundred cancer-regulatory
programs [6]. The release of Oncomine 3.0, which occurred
in January 2006, marks significant additions in data and
functionality. Our semiautomated data pipeline has allowed
us to keep pace with the rapidly growing body of published
data, increasing the number of collected data sets to 264
and increasing the number of profiled cancer and normal
tissue samples to nearly 20,000. In addition, 1000+ gene
expression signatures have now been derived by group-
ing the samples based on carefully curated sample facts
ranging from cancer diagnosis, to transforming mechanism,
to patient survival. Additional analysis methods, including
Molecular Concepts Analysis, Interactome Analysis, and
Meta-Analysis, have been developed [7]. Another important
addition was the implementation of Cancer Outlier Profile
Analysis (COPA) for identifying genes with marked over-
expression in a subset of cases in a given data set. COPA
was used to nominate ERG and ETV1 as candidate onco-
genes in prostate cancer [8].
In addition to a growing database and new analysis
functionality, the Oncomine userbase has also continued to
grow. To date, Oncomine has registered 10,431 users. On
average, > 1000 distinct users log on per month, totaling
approximately 3200 unique sessions and > 100,000 hits per
month. A recent literature review identified 83 articles ref-
erencing the use of Oncomine. A compilation of these ref-
erences is available at http://www.oncomine.org from the
publications link under the About tab.
Oncomine Database and Data Pipeline
The Oncomine project consists of three general layers:
data input, data analysis, and data visualization, with the
Oncomine database playing a central role in storing micro-
array data, sample data, and analysis results (Figure 1). The
data input layer has two components: microarray data pipe-
line and annotation data warehouse. The microarray pipe-
line provides tools for our data collection team to identify,
prioritize, and collect microarray studies from published liter-
ature. The pipeline also draws relevant data sets directly
from the Stanford Microarray Database [9] and the NCBI
Gene Expression Omnibus [3] as they become available.
Importantly, our data collection team consists of pathologists,
molecular biologists, and bioinformatics scientists who care-
fully review cancer microarray studies, including only those
that meet our quality standards. To date, our data collection
team has incorporated 264 independent data sets, totaling
> 18,000 microarray experiments, which span 35 cancer
types (Table 1). A complete list of studies and their PubMed
citations is available in the Oncomine catalog.
The annotation warehouse represents our live compila-
tion of 14 external databases that we have deemed useful
for interpreting the role of individual genes in cancer and
for filtering cancer signatures (Table 2). A series of scripts
checks each of these databases for new data or modifica-
tions and automatically updates the warehouse. Both the
microarray pipeline and the components of the annotation
warehouse feed directly into the Oncomine database. The
database is implemented in Oracle 9i (Oracle, Redwood
Shores, CA) and comprises approximately 80 tables and
300 GB of disk space.
The data analysis layer consists of sample facts standard-
ization and automated statistical analysis. Because micro-
array data are only as valuable as the sample information
accompanying them, our data collection team places special
emphasis on sample facts curation and standardization. In
many cases, this permits us to test hypotheses not explored
in original analyses and publications (e.g., genes associated
with Ras mutation status in lung adenocarcinoma). When
possible, sample facts are translated to standard terms used
by the NCI Thesaurus [10], allowing us to provide definitions
for clinical terms. Automated statistical analysis components
monitor the database for new data and sample attributes,
automatically performing logical differential expression anal-
yses, cluster analyses, and gene set enrichment analyses
when needed. The details of analysis modules are discussed
in the following sections. Lastly, the Oncomine web layer
queries data from the Oncomine database and displays
tabular and graphical representations of data and analysis
results online. The web layer is implemented in Java/JSP
(Sun Microsystems, Santa Clara, CA) and uses dynamic
scalable vector graphics.
Differential Expression
Differential expression analysis forms the crux of the
Oncomine resource. Unlike other microarray repositories,
Oncomine automatically computes differential expression
profiles for cancer types and subtypes so that they can be
easily queried for a gene or pathology of interest. Furthermore,
precomputed differential expression profiles serve as input for
more advanced analytic functions such as Meta-Analysis,
Interactome Analysis, and Enrichment Analysis. We use
Student’s t test for two class differential expression analyses
(e.g., prostate cancer tissues versus normal prostate tis-
sues) and Pearson’s correlation for multiclass ordinal analy-
ses (e.g., Grade I, II, and III breast cancer). In two-class
analyses,we consider genes ‘‘overexpressed’’ if theyaremore
highly expressed in class 2 relative to class 1, whereas in
multiclass analyses, we consider genes overexpressed if they
display progressively increasing expression with increasing
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attribute values (e.g., Grade I < Grade II < Grade III). P values
are corrected for multiple hypothesis testing using the false
discovery rate method, as described by Storey and Tibshirani
[11]. To date, 1120 differential expression analyses have
been performed, of which 847 (76%) found statistically signifi-
cant differences in gene expression (Table 3). Each analysis
represents a logical grouping of samples based on standard-
ized sample facts followed by a t-test or correlation analysis of
each available gene. Types of analysis include ‘‘cancer versus
normal,’’ which compares cancer samples to normal samples
of the same tissue type; ‘‘cancer versus cancer,’’ which com-
pares distinct types and subtypes of cancer; ‘‘molecular alter-
ation,’’ which compares cancer samples of the same type
that differ in mutation status or karyotype; ‘‘prognosis,’’ which
Figure 1. Oncomine consists of three layers: data input, data analysis, and data visualization, with the Oncomine database playing a central role. The data input
layer has two components: the microarray data pipeline and the annotation data warehouse. The microarray pipeline is used internally to identify and prioritize
microarray studies in the literature. The pipeline also draws data directly from the Stanford Microarray Database and the NCBI Gene Expression Omnibus. The
annotation warehouse represents our live compilation of > 10 external databases that were deemed useful for interpreting a gene’s role in cancer. The Oncomine
database is an Oracle 9i relational database. The data analysis layer consists of sample facts standardization and automated statistical analysis. Sample facts
standardization uses the NCI Thesaurus and manual annotation. The automated statistical analysis component is implemented in Perl and R. A series of scripts
monitors the database for new data and sample parameters and automatically performs differential expression analysis, cluster analysis, and gene set analysis,
when needed. Oncomine web servers query data from the Oncomine database and display tabular and graphical representations of data and analysis results. The
web layer is implemented in Java/JSP and creates dynamic SVG.
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compares samples based on patient outcome; and ‘‘histologic
subtype,’’ ‘‘grade,’’ and ‘‘stage,’’ which compare samples
based on these pathological parameters. Analyses of the
‘‘Misc’’ type compare samples based on miscellaneous at-
tributes, including treatment response, viral infection status,
gene expression–based subgroups, and biomarker status
(e.g., estrogen receptor), among others. The analyses per-
formed in Oncomine usually encompass the original analy-
ses performed by the study authors, as well several novel
analyses deemed relevant by our data collection team. A de-
tailed description of the analyses performed can be viewed
by following the ‘‘Browse All Profiles’’ link.
To demonstrate the utility of the Oncomine database
and precomputed differential expression profiles, we queried
differential expression results for the three protein ki-
nases Abl, KIT, and PDGFRa, all of which are inhibited by
the tyrosine kinase inhibitor imatinib mesylate (Gleevec;
Novartis, East Hanover, NJ) (as reviewed in Wong and
Witte [12]) (Figure 2). Gleevec is indicated for chronic lym-
phocytic leukemia with BCR-ABL translocations [13] and for
gastrointestinal stromal tumors (GISTs) with activating KIT
mutations [14]. We anticipated that an Oncomine expression
analysis might identify cancer types and subtypes that over-
express Gleevec targets and, thus, might be susceptible to
inhibition, as is the case with FLT3 inhibition. Interestingly,
when considering all 113 molecular alteration profiles, ABL1
was found to be most significantly overexpressed in leu-
kemias with BCR-ABL translocations relative to leukemias
with other translocations, suggesting that activating trans-
location also leads to relative overexpression (Figure 2A).
Table 1. Data Collection Summary.
Tissue (n) Studies (n) Samples (n)
Adrenal 2 92
Bladder 2 135
Blood 1 60
Brain 18 950
Breast 38 3,198
Cell line 28 1,062
Cervix 1 33
Chondrosarcoma 1 36
Colon 8 422
Endocrine 1 43
Endometrium 5 176
Esophagus 2 71
Gastric 4 303
Head–neck 5 299
Leukemia 25 2,106
Liver 4 404
Lung 12 953
Lymphoma 16 1,929
Melanoma 8 300
Mesothelioma 3 169
Multicancer 8 1,607
Muscle 1 22
Myeloma 7 692
Neuroblastoma 1 112
Normal 4 320
Oral 1 27
Others 1 74
Ovarian 12 524
Pancreas 5 175
Parathyroid 1 61
Prostate 16 851
Rectum 1 46
Renal 9 731
Salivary gland 1 22
Sarcoma 8 591
Seminoma 1 107
Skin 1 18
Thyroid 1 16
Uterus 1 24
264 18,761
Data sets are grouped by tissue type. Studies that profiled several cancer
types are designated ‘‘Multicancer.’’ Studies that profiled only normal human
tissue samples are designated ‘‘Normal.’’ In general, Oncomine contains
primary tissue samples. 28 cancer cell line data sets are also included
(designated ‘‘Cell line’’).
‘‘Studies’’ refers to peer-reviewed publications that profiled z 10 human
cancer or normal samples and provided supplementary microarray data.
‘‘Samples’’ indicates the number of independent tissue samples, each pro-
filed on an individual microarray.
Table 2. External Resources Integrated into the Oncomine Data Warehouse.
Source Type
GenBank Nucleotide sequence
Entrez Gene Gene
Swissprot/Trembl Protein
Unigene EST cluster
InterPro Protein domains and families
Biocarta Pathway
KEGG Pathway
HPRD Protein –protein interactions
Cancer Gene Database* Literature-defined cancer genes
Gene Ontology Process, function, and
localization annotation
Inparanoid Orthologs
Pin database Nuclear protein complexes
Therapeutic Target Database Drug target
TRANSFAC/Match Putative transcription
factor –binding sites
The data warehouse provides annotation for Oncomine genes and reporters.
*The Cancer Gene Database is no longer available online.
Table 3. Differential Expression Analysis Summary.
Type n Significant [n (%)]
Cancer versus cancer 249 234 (93.9)
Molecular alteration 113 96 (85.0)
Normal versus normal 64 64 (100.0)
Cancer versus normal 66 60 (94.0)
Tumor stage 61 19 (31.1)
Histologic subtype 57 53 (93.0)
Tumor grade 56 30 (53.6)
Prognosis 39 18 (46.1)
Miscellaneous 415 273 (65.8)
1120 847 (75.6)
Differential expression analyses were performed on 264 data sets and were
of nine general types. The number of analyses performed is given, as is the
number and the percentage of those analyses that resulted in statistically
significant differential expression signatures. Cancer-versus-cancer analyses
compared one cancer type (e.g., small cell lung cancer) to one or more other
cancer types (e.g., lung adenocarcinoma and lung squamous cell carcinoma).
Molecular alteration analyses compared distinct molecular alterations
observed in a single cancer type (e.g., FLT3 mutation in acute lymphoblastic
leukemia). Normal-versus-normal analyses compared one normal tissue type
to other normal tissue types. Cancer-versus-normal analyses compared
tumors to the normal tissue of origin. Tumor stage, histologic subtype, and
tumor grade analyses compared tumors of a single type based on these
pathological parameters, and prognosis analyses compared tumors from
patients with favorable clinical outcomes to tumors from patients with poor
outcomes (e.g., recurrence, death, and so on).
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Similarly, KIT was found to be most highly expressed in GIST
relative to other soft-tissue sarcomas in two independent
data sets, suggesting that activating mutations in KIT,
which are known to occur in > 80% of GIST, are also asso-
ciated with overexpression (Figure 2B). Interestingly, KIT
was also found to be overexpressed in multiple myeloma
relative to normal B cells, and in seminoma relative to normal
testes. Finally, PDGFRa showed significant overexpression
in the subset of GIST with PDGFRa mutations relative to
those with KIT mutations (Figure 2C). Although PDGFRa
mutations are present in only a small minority of GIST, it
is notable that, again, activating mutations are associated
with overexpression. PDGFRa also showed marked over-
expression in tumor samples relative to cultured cell lines of
the same type, highlighting the importance of PDGFRa
in vivo, consistent with the protein’s documented role in
angiogenesis [15]. Lastly, PDGFRa showed overexpression
in sarcomas relative to melanomas, specifically in synovial
sarcomas (Figure 2D).
The preceding analyses began with genes of interest
and examined their differential expression profiles across
the database of 18,000 microarray experiments. Similar
Figure 2. Selected expression profiles of Gleevec targets: ABL1, KIT, and PDGFRa. (A) Among 71 molecular alteration analyses, ABL1 was most significantly
overexpressed in leukemias with BCR-ABL translocations relative to leukemias with other translocations. (B) Among 67 cancer-type analyses, KIT was most
significantly overexpressed in GISTs relative to other soft-tissue tumors. KIT was also found to be significantly overexpressed in multiple myeloma (MM) relative to
normal B cells, and in seminoma relative to normal testes. (C) PDGFRa was significantly overexpressed in PDGFRa mutant GISTs relative to KIT mutant GISTs,
suggesting that activating mutations are associated with overexpression. In two independent data sets, PDGFRa is overexpressed in primary tumors relative to
cultured tumor cells, highlighting the importance of PDGFRa in tumor–host interactions. Finally, PDGFRa shows overexpression in soft-tissue sarcomas relative to
melanomas. (D) Across a panel of sarcomas, PDGFRa shows overexpression in a fraction of the GISTs and in all synovial sarcomas, but not in clear cell sarcoma,
liposarcoma, or leiomyosarcoma. Moderate expression was observed in fibrosarcomas and malignant fibrous histiocytoma (MFH). The number of samples is
provided in parenthesis, and data sets are named by author and tissue. The y-axis units are based on z-score normalization.
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analyses can be performed online for nearly every named
gene and thousands of expressed sequence tags (ESTs).
Oncomine data can also be explored through the profile mod-
ule, in which a cancer type or subtype of interest is analyzed.
Gene lists and heatmaps can be generated for each of
the > 500 cancer profiles, rank-ordering genes based on
their differential expression. In addition, external filters
can be applied to rank-ordered gene expression profiles.
For example, one might wish to examine overexpressed re-
ceptor tyrosine kinases in pancreatic adenocarcinoma or
underexpressed tumor-suppressor genes in small cell lung
cancer. Filters based on Gene Ontology annotations [16],
InterPro protein domains and families [17], Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) [18] and Biocarta
pathways, chromosome localization, and transcription factor–
binding sites are available [19].
To illustrate the utility of the profile module, we examined
the differential expression of known therapeutic targets
in metastatic prostate cancer (Figure 3). The known thera-
peutic target filter includes 347 genes encoding proteins that
Figure 3. Therapeutics targets overexpressed in prostate cancer progression. (A) Twenty of 337 genes that encode known therapeutic targets that are mostly
overexpressed in the progression from benign prostate (BPH = benign prostatic hyperplasia; NAP = normal adjacent prostate) to localized prostate cancer (PCa) to
metastatic prostate cancer. (B) PRKCZ, the most overexpressed drug target in metastatic prostate cancer, has also been significantly overexpressed in prostate
cancer in two independent data sets PRKCZ is targeted by bisindolylmaleimide I, and its inhibition has been shown to arrest growth in glioblastoma cells [20]. (C)
SHMT2 is another drug target that is overexpressed in prostate cancer progression. The expression pattern is validated by an analogous data set SHMT2 is a
mitochondrial serine hydroxymethyltransferase that is specifically inhibited by the plant amino acid mimosine [21].
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have literature-defined inhibitors, antagonists, or blockers,
according to the Therapeutic Target Database. We exam-
ined the metastatic prostate cancer profile because this ad-
vanced disease is invariably lethal. As depicted in Figure 3A,
several of the 347 known therapeutic targets have in-
creasing expression, with progression from benign prostate
tissue to localized prostate carcinoma to metastatic prostate
cancer. PRKCZ, the ~ isoform of protein kinase C, was found
to be the most significantly overexpressed target in prostate
cancer progression (Figure 3B). This overexpression in pros-
tate cancer was validated by two independent profiles: the
Su et al. profile, which compared prostate cancer to other
cancer types, and the Luo et al. profile, which compared
prostate cancer to normal prostate tissue. PRKCZ is targeted
by bisindolylmaleimide I, and its inhibition has been shown
to arrest growth in glioblastoma cells [20]. Perhaps a simi-
lar effect would be observed in metastatic prostate cancer
given the gene’s strong overexpression profile. Another
target, serine hydroxymethyltransferase 2 (SHMT2), also
showed significantly increased expression in metastatic
prostate cancer, both in the Dhanasekaran and Lapointe
data sets (Figure 3C). In fact, of all Oncomine profiles con-
sidered, SHMT2 had the most significant overexpression in
these two prostate cancer progression profiles. SHMT2 is a
mitochondrial serine hydroxymethyltransferase that is spe-
cifically inhibited by the plant amino acid mimosine [21].
These results suggest that mimosine or derivative com-
pounds should be investigated as prostate cancer therapeu-
tics. In summary, gene and profile modules can be used to
examine differential expression results in the context of a
gene or pathology of interest.
Coexpression
Coexpression analysis seeks to identify sets of genes with
synchronous expression patterns across a panel of tissue
samples. Several studies have demonstrated that coexpres-
sion often suggests shared function; thus, when considering
a target or marker of interest, it is helpful to study genes
with shared expression patterns. We apply average linkage
hierarchical clustering to identify sets of coexpressed genes
in each Oncomine data set. To prioritize cluster results for a
gene of interest, clusters from independent studies are
sorted based on their size and intracorrelation. In some data
sets, a gene of interest may show little variation and may
have no coexpressed genes, whereas in other data sets,
the gene of interest may be part of a robust cluster of co-
expressed genes. For example, we queried coexpression
results for ERBB2 (Her2/neu), a receptor tyrosine kinase
amplified in breast cancer, and found that it was part of
a strong cluster of 14 genes (R = 0.56) across a panel of
295 breast carcinoma samples (Figure 4A). Interestingly,
when examining the coexpressed genes, we found that all
of them are located on chromosome 17q, adjacent to ERBB2.
This is consistent with previous reports stating that genes
from the ERBB2 amplicon are coamplified and coexpressed
in breast cancer [22]. Interestingly, GRB7, which is located
immediately adjacent to ERBB2, showed remarkably strong
coexpression with ERBB2 (R = 0.92) (Figure 4B), suggest-
ing that DNA copy number strongly influences the expression
levels of these two genes.
Meta-Analysis
One advantage to compiling large numbers of microarray
studies in a single database is that the results of different
studies can be compared directly. For example, one problem
with microarray studies is that false-positive results are
common [5]. Another is that microarray studies often gen-
erate gene signatures consisting of hundreds of genes,
making it difficult to distinguish which genetic features are
critical. In these types of situations, it would be useful to
compare the results of different studies, to determine which
results are most robust and most consistent across a range
of studies. Comparative meta-profiling is a method designed
to permit the comparison of different studies present in the
Oncomine database. There are many problems associated
with comparing actual gene measurements across dispa-
rate microarray data sets; comparative meta-profiling was
designed to avoid these problems by instead comparing
differential expression measured in each data set [5]. With
Oncomine, users first select appropriate studies for com-
parison, and then use meta-analysis to identify the genes
that are significantly overexpressed or underexpressed
across multiple independent studies. A ‘‘leave-one-out’’
strategy is incorporated to compensate for arrays in which
a particular gene is not represented or is not well measured.
Meta-analysis will become increasingly useful as the num-
ber of published transcriptome studies continues to grow
and as these studies are added to the Oncomine database.
COPA
COPA, the most recent addition to the Oncomine analysis
pipeline, searches for gene expression profiles that display
the most profound overexpression in a subset of tumors [8].
This methodology was motivated by the heterogeneity of
cancer and the fact that oncogenes are often activated in
only a subset of cases. As described previously, COPA cor-
rectly prioritized several known oncogenes in their respective
tumor types, including ERBB2 in breast cancer, CCND1 and
FGFR3 in multiple myeloma, and PBX1 in leukemia, among
others. Also of note, COPA nominated ERG and ETV1 as
having profound outlier expression in subsets of prostate
tumors, which was validated experimentally and shown to
be the result of gene fusion events with the androgen-
regulated gene TMPRSS2 [8]. Results from COPA are avail-
able from both gene and profile modules. Within the gene
module, an outlier tab reports an ordered list of data sets
in which the query gene had the highest ranking COPA
score. The summary page also depicts COPA results in the
last column, allowing one to quickly identify cancer types in
which query genes frequently show marked outlier expres-
sion. For example, a gene search for ERBB2 shows that 11
independent breast cancer data sets rank ERBB2 in the top
50 scoring outliers, whereas no prostate cancer data set
ranks ERBB2 in the top 50. Conversely, a gene search for
ERG identifies nine independent prostate cancer data sets
ranking ERG in the top 50 outliers, whereas no breast cancer
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data set ranks ERG in the top 50. Figure 5 depicts outlier
profiles of ERBB2 and ERG in breast and prostate cancer
data sets, respectively. Outlier results are also available
through the profilemodule under advanced analysis, allowing
one to identify top-scoring outliers in a given data set. As
described for differential expression analysis, standard filters
for identifying top-scoring outliers within a selected subset of
genes are also available.
Work Flow
Analyses in Oncomine can be initiated from one of four
possible starting points: Gene Search, Profile Search,
Browse Profiles, or Browse Catalog. Gene Search is used
to explore Oncomine with a gene of interest. A search on
any gene returns a Differential Activity Map, a visual sum-
mary of all the tissues and comparison types in which
that gene is differentially expressed, at a level of statistical
Figure 4. ERBB2 cluster in invasive breast carcinoma. (A) ERBB2 is coexpressed (R = 0.56) with 14 genes across a panel of 295 breast carcinoma samples
(101 cases that went on to metastasize are shown). All 14 genes are located near ERBB2 on chromosome 17q, suggesting that coexpression can be attributed
to known amplification of this region in breast carcinoma. (B) GRB7 is immediately adjacent to ERBB2 and displays a nearly identical expression pattern (R = 0.91)
across the breast carcinoma samples, indicating that GRB7 is coexpressed and likely coamplified with ERBB2 in all cases.
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significance that is determined by the user. Users then focus
on a specific tissue and comparison type (e.g., prostate;
cancer vs normal), or a particular analysis type (Differen-
tial Expression, Co-expression, or Outlier Analysis). Profile
Search is built on differential expression analyses performed
on individual studies, which generate lists of genes (‘‘gene
signatures’’) that are differentially expressed between two
related tissue or cell types. In Profile Search, users can
access the gene signatures of particular cancer, treatment,
histology, or pathology parameters. Once identified, those
profiles can be analyzed across studies using meta-analysis.
Alternatively, the results of any given study can be explored
using a variety of tools, including Differential Expression,
Filter, Enrichment, Interactome, Pathway, and Outlier Anal-
ysis. Browse Profiles permits users to initiate a search of all
profile analyses present in Oncomine without applying any
initial filters. Browse Catalogs returns all studies in the
Oncomine catalog. Filtering is available to limit searches to
specific tissues or by analysis status.
Methods
Data Collection, Processing, and Storage
Microarray data sets were downloaded from author web
sites, provided by the authors on request, or downloaded from
the Stanford Microarray Database [9] or the Gene Expression
Omnibus [3]. A list of collected data sets is available from
the Oncomine catalog. Data were of two general types (two-
channel ratio data and single-channel intensity data) and were
usually provided in a single composite file format. All available
data were included in processing and analysis, except for
negative single-channel intensity values. All data sets were
log-transformed and median-centered per array, and stan-
dard deviations were normalized to one per array. Studies
were named by the following convention: FirstAuthor_
TissueTypeProfiled (e.g., Dhanasekaran_Prostate). Sample
attributes were standardized and linked to NCI Thesaurus
terms [10] by our data collection team. Data and analysis re-
sults were stored in an Oracle 9i relational database.
Figure 5. COPA indicates that ERBB2 and ERG exhibit outlier expression in multiple breast and prostate cancer microarray data sets, respectively. (A) ERBB2
expression profile in the Perou et al. [31] cDNA microarray data set. (B) ERBB2 expression profile in the van de Vijver et al. [32] oligonucleotide data set,
segregated by estrogen receptor (ER) status. (C) ERG expression profile in a cDNA microarray data set. (D) ERG expression profile in an oligonucleotide data set,
segregated by Gleason score.
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Differential Expression Analysis
For each of the collected data sets, samples were
reviewed and grouped into logical sample sets. To date,
264 data sets have been reviewed, with at least four samples
corresponding to both classes of one analysis of interest
and further analyzed. Analyses of interest included: cancer
tissue versus respective normal tissue; high-grade (un-
differentiated) cancer versus low-grade (differentiated)
cancer; poor-outcome (metastases, recurrence, or cancer-
specific death) cancer versus good-outcome (long-term or
recurrence-free survival) cancer; metastasis versus primary
cancer; and various molecular subtypes, biomarker status,
treatment responses, and other miscellaneous comparisons.
After the definition of logical analyses, each gene was
assessed for differential expression with Student’s t test, in
the case of two-class analyses, and with Pearson’s correla-
tion, in the case of multiclass ordinal analyses. Both tests
were performed using the R statistical computing package
(http://www.r-project.org). Tests were conducted both as
two-sided, for differential expression analysis, and as one-
sided, for overexpression analysis. To account for multiple
hypothesis testing, Q values (estimated false discovery
rates) were calculated as follows: Q = NP / R, where P is
P value, N is the total number of genes analyzed, and R is
the sorted rank of P value.
Coexpression Analysis
Each data set was filtered to contain only the top 50%most
variable genes, as defined by standard deviation. Next, aver-
age linkage hierarchical clustering was performed on each
data set using AlgorithmDCluster for Perl (http://bonsai.ims.
utokyo. ac.jp/~mdehoon/software/cluster/software.htm). The
Oncomine application sorts coexpression results by node
correlation for all nodes having at least 10 distinct genes. This
allows users to focus on data sets in which a gene of interest
displays a strong coexpression with other genes.
COPA
COPA has three simple steps. First, gene expression
values are median-centered, setting each gene’s median ex-
pression value to zero. Second, median absolute deviation
(MAD) is calculated and scaled to 1 by dividing each gene
expression value by its MAD. Of note, median andMADwere
used for transformation, as opposed to mean and standard
deviation, so that outlier expression values do not unduly in-
fluence distribution estimates and are, thus, preserved post-
normalization. Third, the 75th, 90th, and 95th percentiles of
transformed expression values are tabulated for each gene,
and then genes are rank-ordered by their percentile scores,
providing a prioritized list of outlier profiles.
Molecular Concept Data Collection and Analysis
Sets of biologically related genes were collected or de-
rived from 503 microarray studies and 12 external data-
bases. All identifiers were mapped to Entrez Gene IDs for
analysis. For each molecular concept, a null set was defined
as the set of all genesmeasured or considered in defining the
concept. For example, null sets for microarray-based con-
cepts were defined as all genes measured on a microarray
platform, whereas null sets for Gene Ontology–based con-
cepts were defined as all genes with at least one Gene
Ontology annotation.
Cancer signatures were derived from differential expres-
sion analyses that compared two logical groupings of normal
or malignant human tissues or cell lines as defined by
the Oncomine Cancer Microarray Database (http://www.
oncomine.org) [5]. In total, data from f 18,000 microarrays
from 270 independent studies were used in this analysis.
From Oncomine, we downloaded gene lists rank-ordered by
P values by Student’s t test from 1192 differential expres-
sion analyses. We defined gene signatures as the top 1%,
5%, and 10% of overexpressed or underexpressed genes
from each analysis. We selected multiple cutoffs to allow for
variability in the optimal association cutoff. Only the most
significant of the three cutoffs is reported. Drug overexpres-
sion and underexpression signatures were derived from the
Connectivity Map data set [28]. The data set was normalized
as described [5], except that normalized expression values
of <  0.5 were set to  0.5. Each compound treatment
experiment was compared to the appropriate control ex-
periment(s) based on the assigned batch number. When
multiple replicates were available, expression values were
averaged. Genes that did not have a normalized expression
value of > 0.0 in either treatment or control experiments
were further filtered. Genes were then rank-ordered by over-
expression and underexpression in treatment versus control,
and the top 1% and 5% overexpression and underexpres-
sion genes were assigned to molecular concepts.
Table 4. Molecular Concept Types Integrated for Enrichment Analysis.
Class Source Type Concepts
Annotation Gene Ontology Biologic process 855
Cellular component 249
Molecular function 818
InterPro Protein family 2072
Gene expression Oncomine Cancer signatures* 2382
Literature Perturbation signatures 485
Connectivity
Map
Drug signatures* 758
Regulatory TRANSFAC Promoter-binding site sets 361
picTar miRNA target sets 168
Broad Conserved promoter motif 174
Conserved UTR motif 72
Cytogenetic NCBI Chromosome arm 47
Chromosome subregion 294
Pathways/ Biocarta Signaling pathways 260
interactions KEGG Metabolic pathways 160
HPRD Ptn–Ptn interaction sets 4144
PINdb Nuclear protein complex 65
Five classes of molecular concepts were compiled from 13 sources.
Oncomine and literature concepts were derived by integrating data from
many independent sources.
PINdb = Proteins Interacting in the Nucleus database.
*The number of concepts reported includes one overexpression signature
and one underexpression signature from each Oncomine and Connectivity
Map profile. Concepts were generated from three overexpression and three
underexpression Oncomine signatures (top 1%, 5%, and 10%) and two
overexpression and underexpression Connectivity Map signatures (top 1%
and 5%).
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Chromosome arm and cytoband mappings were down-
loaded from the NCBI Map Viewer (http://www.ncbi.nlm.nih.
gov/mapview/). Biologic process, molecular function, and
cellular component annotations from the Gene Ontology
Consortium (http://www.geneontology.org/) [16] were down-
loaded from Entrez Gene (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=gene). KEGG metabolic pathways
were downloaded from KEGG (http://www.genome.jp/
kegg/) [18]. Biocarta signaling pathways were downloaded
from the Biocarta web site (http://www.biocarta.com/). Pro-
tein domains and family assignments were downloaded
from InterPro (http://www.ebi.ac.uk/interpro/) [17]. Protein–
protein interaction sets were downloaded from the Human
Protein Reference Database (HPRD; http://www.hprd.org/)
[24]. Literature-defined concepts were collected from 207
peer-reviewed publications that applied Affymetrix arrays to
study the transcriptional effects of an experimental perturba-
tion such as drug treatment or candidate gene activation.
TRANSFAC (http://www.gene-regulation.com) transcrip-
tion factor motifs were defined by scanning all human gene
promoter sequences for the presence of 361 experimentally
defined transcription factor–binding sites [19]. One-kilobase
promoter sequences from 20,647 RefSeqs were downloaded
from the UCSC genome browser (http://hgdownload.cse.
ucsc.edu/goldenPath/hg17/bigZips/) in August 2004. Se-
quences were sequentially submitted to MATCH a compo-
nent of the TRANSFAC Professional Suite, which scans a
sequence for the presence of transcription factor–binding
sites as determined by a database of position–weight matri-
ces. A hit list was filtered to contain only the top 2000 hits per
matrix, as sorted by the matrix similarity score. Conserved
promoter motifs and conserved 3V UTR motifs were defined
by a comparative genomics analysis that identified conserved
motifs across four mammalian organisms [29]. Predicted
microRNA target genes were downloaded from picTar
(http://pictar.bio.nyu.edu/), a resource that applies a com-
parative genomics algorithm to identify putative miRNA
target gene sets [30].
To carry out molecular concepts analysis, each pair of
molecular concepts was tested for association using Fisher’s
exact test. Results were stored if a given test had odds ratio
(OR) > 1.25 and P < .01. P < 1e  100 was set to 1e  100.
Interactome
Approximately 16,000 known protein–protein interac-
tions were downloaded from the Human Protein Reference
Figure 6. Analyzing cancer signatures in the context of related gene sets can identify coordinately regulated functional modules. To test for the enrichment of
related gene sets in cancer signatures, the overlap is assessed as a 2  2 contingency table, and then a Fisher’s exact test is performed. Related gene set analysis
is automatically performed for a wide variety of gene sets across hundreds of cancer signatures from the Oncomine database.
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Database (http://www.hprd.org). The HPRD interaction set
represents a manually curated database of proteins pairs that
have experimental evidence for physical interaction. Each
protein–protein interaction is linked to literature evidence.
Oncomine reports pairs of differentially expressed genes
that encode proteins with documented protein–protein inter-
actions. Gene pairs are rank-ordered by the product of their
P values. Oncomine generates interactome maps for the top
10% of genes rank-ordered by their P values in each differ-
ential expression analysis.
Molecular Concepts Analysis
The previous sections detailed analyses at the level of indi-
vidual genes. Recent reports have demonstrated that focusing
instead on sets of related genes (e.g., pathways, processes,
protein complexes, and so on) can uncover relationships
not apparent at the single-gene level [23]. For example, one
might observe that TOP2A is overexpressed in aggressive
breast cancer and might conclude that this gene plays an
important role in tumorigenesis. An analysis of related gene
sets, or ‘‘molecular concepts,’’ might show that, in fact, the
cell cycle gene set, of which TOP2A is a part, is disproportion-
ately overexpressed in aggressive breast cancer, allowing
for the more accurate and more general conclusion that the
cell cycle is hyperactivated in aggressive breast cancer. In
another case, one might find that a disproportionate fraction
of differentially expressed genes share Myc-binding sites in
their promoters, suggesting that pathways activating the Myc
transcription factor might be responsible for observed gene
deregulation and cancer pathogenesis.
To identify such functional and regulatory relationships,
the Oncomine analysis pipeline includes a comprehensive
‘‘molecular concepts’’ analysis, which spans diverse types
of gene sets, including those derived from Gene Ontology
[16], InterPro [17], Biocarta, KEGG [18], HPRD [24], and
TRANSFAC [19], as well from Oncomine itself and our
newly developed resource, the Molecular Concept Map
(D.R.R., unpublished data) (Table 4). For each gene expres-
sion signature in Oncomine, this analysis provides a broad
Figure 7. Molecular concepts analysis of cancer signatures. Oncomine analyzes 13 types of molecular concepts (Table 4) and searches for significant enrichment
in cancer and normal tissue signatures. Signatures were computed for each cancer type in the Su et al. multicancer data set [25], and representative enriched
molecular concepts are presented. Each row in the heatmap represents a gene in the labeled molecular concept. Red indicates relative overexpression, and blue
indicates relative underexpression. Fatty acid metabolism genes were enriched in the prostate cancer signature; protein metabolism genes were enriched in the
colorectal cancer signature; immunoglobulin-like genes were enriched in the renal cell carcinoma signature; and proteolysis gene were enriched in the pancreatic
cancer signature.
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understanding of activated and repressed processes, path-
ways, and regulatory programs, while also drawing similarity
to Oncomine-derived signatures and experimentally defined
signatures from the literature.
Molecular concepts analysis automatically compares
each gene set to each Oncomine cancer signature, assess-
ing overlap significance with Fisher’s exact test (Figure 6).
The Oncomine enrichment module then sorts gene sets of
each type based on their degree of enrichment in a selected
expression signature. To illustrate the utility of this analysis
module, we inspected the results generated for cancer sig-
natures from the Su et al. multicancer data set [25]. This
data set included 11 types of cancer, and Oncomine differ-
ential expression analysis generated signatures of genes
deregulated in each cancer type relative to all others. Mo-
lecular concepts analysis on these differential expression
profiles identified molecular concepts that are coordinately
overexpressed in the respective cancer types. For ex-
ample, as depicted in Figure 7, prostate cancers showed
overexpression of fatty acid metabolism genes, whereas
colorectal cancers showed relative overexpression of protein
metabolism genes. Renal cell carcinomas showed over-
expression of immunoglobulin-like genes, perhaps due to
white blood cell infiltrates, and pancreatic cancers showed
coordinate overexpression of proteolysis genes. These re-
sults can be reviewed in detail by visiting the Enrichment
Analysis in Oncomine. The same type of analysis has been
performed for each of the > 1000 Oncomine cancer signa-
tures. We recently applied this analysis module to examine
molecular concepts that are deregulated in prostate cancer
Figure 8. Protein interaction networks overexpressed in multiple myeloma. (A) Heatmaps depicting the overexpression of the RAF1 and IARS networks in multiple
myeloma relative to normal B cells. Seven of 42 interactions partners of RAF1 are in the top 5% of the myeloma profile (OR = 4.35, P = .004), and 9 of 10 interaction
partners of IARS are in the top 20% of the myeloma profile (OR = 21.58, P = 2.6e  6). (B) The extended RAF1 network overexpressed in multiple myeloma
displaying the multifaceted activation of RAF1. (C) The IARS network overexpressed in multiple myeloma.
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progression based on laser capture microdissection micro-
array profiles, identifying key process and regulatory mech-
anisms at work in cancer progression [26].
Interaction Network Analysis
The Interactome analysis module uses known and pre-
dicted components of the human protein interaction network
as a framework for interpreting complex cancer signatures.
Known protein–protein interactions are queried from the
HPRD [24]. Instead of considering cancer signatures as lists
of deregulated genes, the Interactome module allows one to
consider a multidimensional network of gene deregulation.
This type of analysis, coupled with gene set analysis, facili-
tates the identification of cancer network ‘‘hubs,’’ referring to
overexpressed proteins that interact with a large number
of other overexpressed proteins. For example, when con-
sidering a multiple myeloma signature, we found that both
IARS and RAF1 are overexpressed and interact with a dis-
proportionate number of other overexpressed genes. Seven
of 42 interactions partners of RAF1 are in the top 5% of the
myeloma profile (OR = 4.35, P = .004), and 9 of 10 interaction
partners of IARS are in the top 20% of the myeloma profile
(OR = 21.58, P = 2.6e  6). This enrichment suggests that
these networks are hyperactivated and may thus serve as
appropriate points of intervention (Figure 8). Again, this type
of analysis is available for all Oncomine cancer signatures.
Comparison with Other Resources
Oncomine is unique in that it unifies a large compendium
of published cancer microarray data with a suite of advanced
analytic tools facilitating biologist-friendly data mining. The
ArrayExpress [2] and the Gene Expression Omnibus [3]
repositories have proven highly valuable in standardizing
and distributing cancer microarray data; however, these re-
sources are not focused on data analysis or in-depth data
mining. The Stanford Microarray Database [9] also con-
tains a large number of data sets, but again, the data are
not easily navigated, especially on a per-gene basis. As de-
scribed above, all cancer microarray data that are de-
posited in Gene Expression Omnibus (GEO) and Stanford
Microarray Database (SMD) are automatically ported to
Oncomine and then standardized by our data collection
team. Diehn et al. [27] provide a graphical representation of
microarray data, but only for a limited number of data sets.
In summary, Oncomine is a unique resource offering un-
paralleled access to published cancer transcriptome data.
Availability
Oncomine is freely available to the academic research
community at http://www.oncomine.org and to commer-
cial entities from Compendia Bioscience, Inc. (http://www.
compendiabio.com) at http://www.oncomine.com.
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